Fund Holdings — Lynx1 Capital Management LP

Total Portfolio Value
$346.17M
Total Bought
$53.29M
Total Sold
$0
Net Transaction
+$53.29M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q1 2025
▲▼
Q2 2025
▲▼
Change
▲▼
Q1 2025
▲▼
Q2 2025
▲▼
Weight (%)
▲▼
Change
▲▼
STOKE THERAPEUTICS INC(STOK)5,291,9295,404,674+112,74535,19161,34317.72%+26,152
MERUS N V1,568,8411,568,841066,03382,52123.84%+16,489
GH RESEARCH PLC(GHRS)6,443,9406,746,951+303,01171,07782,24523.76%+11,169
CULLINAN THERAPEUTICS INC(CGEM)3,215,7224,400,842+1,185,12024,34333,1389.57%+8,795
PROTAGONIST THERAPEUTICS INC733,014733,014035,44940,51411.70%+5,065
TSCAN THERAPEUTICS INC(TCRX)5,357,3477,857,347+2,500,0007,39311,3933.29%+4,000
UPSTREAM BIO INC(UPB)219,247219,24701,3422,4070.70%+1,066
PRECISION BIOSCIENCES INC(DTIL)766,0511,036,051+270,0003,6544,3511.26%+697
PASSAGE BIO INC(PASG)9,256,9539,256,95303,2693,7061.07%+437
ASSEMBLY BIOSCIENCES INC010,366+10,36601880.05%+188
NEUPHORIA THERAPEUTICS INC45,80645,80602643250.09%+61
DESIGN THERAPEUTICS INC(DSGN)65,95465,95402552220.06%-32
C4 THERAPEUTICS INC(CCCC)7,098,1337,098,133011,35710,1502.93%-1,207
IBIO INC(IBIO)862,2791,538,573+676,2943,4661,1740.34%-2,292
ALLOGENE THERAPEUTICS INC11,057,00911,057,009016,14312,4943.61%-3,649
Page 1 of 1
Lynx1 Capital Management LP — 13F Holdings — Q2 2025 | TickerTrail